Longeveron Inc.

2:15 PM - 2:30 PM (EST), Tuesday, February 7, 2023 ・ Winter Garden
We are a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions.

Our lead investigational product is Lomecel-B™, which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. We believe that by using the same cells that promote tissue repair, organ maintenance, and immune system function, we can develop safe and effective therapies for some of the most difficult diseases and conditions associated with aging.

We are currently conducting Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS), which is the current exception to our focus on aging.
Ticker:
LGVN
Exchange:
NASDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Florida
Company HQ Country:
United States
Year Founded:
2014
Main Therapeutic Focus:
Gene/Cell Therapy
Lead Product in Development:
Lomecel-B
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
Longeveron LLC